@article {49338,
	title = {Engineered PLGA core-lipid shell hybrid nanocarriers improve the efficacy and safety of irinotecan to combat colon cancer},
	journal = {ACS BIOMATERIALS SCIENCE \& ENGINEERING},
	volume = {10},
	year = {2024},
	month = {SEP},
	pages = {6661-6676},
	type = {Journal Article},
	keywords = {BULK-POLYMERIZATION, Drug-delivery, LIPOSOMAL DOXORUBICIN},
	issn = {2373-9878},
	doi = {10.1021/acsbiomaterials.4c01260},
	author = {Giram, Prabhanjan S. and Nimma, Ramakrishna and Bulbule, Anuradha and Yadav, Amit Singh and Gorain, Mahadeo and Radharani, Nalukurthi Naga Venkata and Kundu, Gopal C. and Garnaik, Baijayantimala}
}
@article {49096,
	title = {Poly(<sc>d</sc>,<sc>l</sc>-lactide-<i>co</i>-glycolide) surface-anchored biotin-loaded irinotecan nanoparticles for active targeting of colon cancer},
	journal = {ACS Omega },
	volume = {9},
	year = {2024},
	month = {JAN },
	pages = {3807-3826},
	type = {Article},
	abstract = {<p>
	A poly-(d,l-lactide-co-glycolide) (PLGA) copolymer was synthesized using the ring-opening polymerization of d,l-lactide and glycolide monomers in the presence of zinc proline complex in bulk through the green route and was well characterized using attenuated total reflectance-Fourier transform infrared, H-1 and C-13 nuclear magnetic resonance, gel permeation chromatography, differential scanning calorimetry, X-ray diffraction, matrix-assisted laser desorption/ionization time-of-flight, etc. Furthermore, PLGA-conjugated biotin (PLGA-B) was synthesized using the synthesized PLGA and was employed to fabricate nanoparticles for irinotecan (Ir) delivery. These nanoparticles (PLGA-NP-Ir and PLGA-B-NP-Ir) were tested for physicochemical and biological characteristics. PLGA-B-NP-Ir exhibited a stronger cellular uptake and anticancer activity as compared to PLGA-NP-Ir in CT-26 cancer cells (log p \&lt; 0.05). The accumulation and retention of fluorescence-labeled nanoparticles were observed to be better in CT-26-inoculated solid tumors in Balb/c mice. The PLGA-B-NP-Ir-treated group inhibited tumor growth significantly more (log p \&lt; 0.001) than the untreated control, PLGA-NP-Ir, and Ir-treated groups. Furthermore, no body weight loss, hematological, and blood biochemical tests demonstrated the nanocarriers{\textquoteright} nontoxic nature. This work presents the use of safe PLGA and the demonstration of a proof-of-concept of biotin surface attached PLGA nanoparticle-mediated active targeted Ir administration to combat colon cancer. To treat colon cancer, PLGA-B-NP-Ir performed better due to specific active tumor targeting and greater cellular uptake due to biotin.</p>
},
	issn = {2470-1343},
	doi = {10.1021/acsomega.3c07833},
	author = {Giram, Prabhanjan S. and Nimma, Ramakrishna and Bulbule, Anuradha and Yadav, Amit Singh and Gorain, Mahadeo and Radharani, Nalukurthi Naga Venkata and Kundu, Gopal C. and Garnaik, Baijayantimala}
}
